Biotech - Spark Newswire

1 minute read

Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings

Today, 12:20 PM

Merck & Co Inc (NYSE:MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen…

MRK

1 minute read

BioAffinity Technologies, Subsidiary Oncoselect Therapeutics, Has Been Granted U.S. Patent Number 11,590,233 Titled “Porphyrin Compounds And Compositions Useful For Treating Cancer”

By Happy Mohamed

Today, 12:20 PM

https://ppubs.uspto.gov/pubwebapp/external.html?q=(11590233).pn

BIAF

2 minute read

Hyperfine, Inc. Receives FDA Clearance For Updated Software To Further Improve Diffusion-Weighted Imaging

By Happy Mohamed

Today, 12:20 PM

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system, today announced the U.S. Food and Drug Administration

HYPR

2 minute read

Kiromic BioPharma Reports Favorable Deltacel Preclinical Pharmacology Results

By Happy Mohamed

Today, 12:20 PM

Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company's IND Application IND Submission and Activation of Clinical Trial Process on Track for the First

KRBP

1 minute read

Incannex Healthcare Has Commenced A Phase 2 Trial To Assess The Safety And Efficacy Of Its Proprietary Anti-inflammatory Combination Drug IHL-675A For Rheumatoid Arthritis

By Benzinga Newsdesk

Today, 12:20 PM

IHL-675A is a proprietary fixed-dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ).

IXHL

1 minute read

Beam Therapeutics Expects Cash, Cash Equivalents, And Marketable Securities Of $1.1B Will Enable The Company To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements At Least Into 2025

By Benzinga Newsdesk

Today, 12:20 PM

This expectation includes funding directed toward reaching each of the key milestones for BEAM-101, BEAM-201, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and

BEAM

2 minute read

Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration

By Happy Mohamed

Today, 12:20 PM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", , Biogen", , ))))

BIIB

4 minute read

DREAM-HF Phase 3 Trial Results For Mesoblast Cell Therapy In Heart Failure Published In Journal Of The American College Of Cardiology

By Happy Mohamed

Today, 12:20 PM

Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed

MESO

2 minute read

Verrica Pharmaceuticals Announces FDA Acceptance Of Filing Of Resubmitted NDA For VP-102 For The Treatment Of Molluscum Contagiosum; Assigns PDUFA goal date of July 23, 2023

By Happy Mohamed

Today, 12:20 PM

Assigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious

VRCA

2 minute read

Aptinyx Reports Results From Phase 2 Study Of NYX-458 In Cognitive Impairment Associated With Parkinson’s Disease And Dementia With Lewy Bodies And Provides Pipeline And Corporate Update; Will Undertake Cost-Cutting Measures And Explore Alternatives

By Happy Mohamed

Today, 12:20 PM

NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company

APTX